Kisspeptin vs PT-141: Comparing the Indexed Record
The practical distance between Kisspeptin and PT-141 shows up first in how much published methodology exists for each.
Compound profiles
Kisspeptin in the indexed record
Kisspeptin returns 3,465 indexed records on PubMed, a substantial record, alongside 45 registered studies on ClinicalTrials.gov.
Journals represented in the current index include Eur J Obstet Gynecol Reprod Biol, Front Endocrinol (Lausanne), J Clin Med, spanning 2019–2024.
- The Role of Kisspeptin in the Control of the Hypothalamic-Pituitary-Gonadal Axis and Reproduction — Front Endocrinol (Lausanne), 2022. PMID: 35837314
- Kisspeptin and Endometriosis-Is There a Link? — J Clin Med, 2024. PMID: 39768606
- Kisspeptin and Glucose Homeostasis — Semin Reprod Med, 2019. PMID: 31869842
- Kisspeptin in the Prediction of Pregnancy Complications — Front Endocrinol (Lausanne), 2022. PMID: 35928889
PT-141 in the indexed record
Indexed output for PT-141 stands at 21 records, a limited literature, alongside 4 registered studies on ClinicalTrials.gov.
Journals represented in the current index include Curr Opin Investig Drugs, Int J Mol Sci, J Sex Med, spanning 2004–2026.
- Bremelanotide — , 2006. PMID: 31369224
- PT-141 Palatin — Curr Opin Investig Drugs, 2004. PMID: 15134289
- Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives — Int J Mol Sci, 2026. PMID: 42123471
- An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist — J Sex Med, 2006. PMID: 16839319
Side-by-side research profile
| Parameter | Kisspeptin | PT-141 |
|---|---|---|
| PubMed indexed records | 3,465 | 21 |
| Registered studies (ClinicalTrials.gov) | 45 | 4 |
| Literature depth | Extensive | Emerging |
| Handling class | Lyophilised powder | Lyophilised powder |
| Designation | Research use only | Research use only |
Classification and why it matters
Kisspeptin and PT-141 sit in different structural classes, and that classification is what determines whether a published protocol for one has any bearing on the other. Peptide research compounds are grouped by sequence length, origin and the receptor families the literature associates with them — not by the outcome a reader might be looking for.
Reading across classes is the most common error in a literature review. A protocol developed for Kisspeptin describes conditions validated for Kisspeptin: concentration ranges, solvent choice, incubation windows and control selection were all established against that compound. Applying those same conditions to PT-141 without re-validation produces data that cannot be compared back to the source publication.
Where the two compounds are studied in overlapping models, the published work almost always treats them as separate arms rather than as substitutes. That separation is the useful signal: it indicates the research record does not consider them equivalent.
How the literature differs
The indexed record is not symmetrical between these two compounds. Kisspeptin carries 3,444 more indexed records than PT-141, which means published methodology, characterisation data and replication attempts are more readily located for Kisspeptin. For a researcher planning a literature review, that asymmetry usually determines which compound has established reference protocols and which requires primary-source work.
Registered study counts (45 vs 4) track a different signal — formal study registration rather than published output — and the two figures frequently diverge.
Documentation standards
Identity and purity are separate claims requiring separate methods. A purity percentage quoted without the analytical method behind it, or a certificate with no lot reference, is a documentation gap rather than verification.
Physical handling notes
Both arrive lyophilised. Standard practice keeps the unopened vial at -20°C, protected from light, and defers reconstitution until the point of use. Solution-phase stability is the limiting factor in most protocols, not powder-phase stability.
Repeated freezing and thawing is the most common avoidable source of degradation.
Selecting between them for a study design
Kisspeptin and PT-141 are not interchangeable. They differ in structural class and in the pathways the literature associates with each, so substituting one for the other changes what a model is actually measuring.
Where a protocol cites a specific compound, the cited compound is the one the published result applies to. Where no protocol exists, the compound with the deeper indexed record (Kisspeptin) generally offers more methodological precedent.
Frequently asked questions
Which of Kisspeptin or PT-141 has more published research?
Kisspeptin, with 3,465 indexed PubMed records against 21.
What is the regulatory status of these compounds?
Neither is an approved drug. Both are supplied strictly for in-vitro laboratory research and are not intended for human or veterinary consumption.
Are Kisspeptin and PT-141 the same compound?
No. They are structurally distinct research compounds with separate literature records — 3,465 indexed records for Kisspeptin and 21 for PT-141.
Related references
Research use only. The compounds discussed are supplied for in-vitro laboratory research. They are not drugs, are not approved for the diagnosis, treatment, cure or prevention of any condition, and are not intended for human or veterinary consumption.